SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-023257
Filing Date
2024-02-29
Accepted
2024-02-29 17:11:11
Documents
20
Period of Report
2024-02-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20240228.htm   iXBRL 8-K 55592
2 EX-1.1 janx-ex1_1.htm EX-1.1 345443
3 EX-4.1 janx-ex4_1.htm EX-4.1 139878
4 EX-5.1 janx-ex5_1.htm EX-5.1 24249
5 EX-99.1 janx-ex99_1.htm EX-99.1 16110
6 EX-99.2 janx-ex99_2.htm EX-99.2 17501
7 GRAPHIC img151594875_0.jpg GRAPHIC 2126
8 GRAPHIC img201480580_0.jpg GRAPHIC 4603
9 GRAPHIC img202404101_0.jpg GRAPHIC 4603
  Complete submission text file 0000950170-24-023257.txt   842309

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240228.xsd EX-101.SCH 31937
21 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240228_htm.xml XML 4898
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 24705029
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)